The Medical Letter on Drugs and Therapeutics
A Mometasone-Eluting Sinus Implant (Sinuva) for Nasal Polyps
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Sinuva (Intersect ENT), a sinus implant that gradually releases the corticosteroid mometasone furoate over a 90-day period, for treatment of nasal polyps in adults who have had ethmoid sinus surgery. Propel, a sinus implant that releases mometasone furoate over 30 days, is FDA-approved to maintain the sinus opening after ethmoid sinus surgery; it is marketed by the same manufacturer as Sinuva.1

NASAL POLYPS — About 25-30% of patients with chronic rhinosinusitis develop nasal polyps (CRSwNP). Symptoms include nasal discharge, congestion, obstruction, and anosmia. An intranasal corticosteroid, such as fluticasone or mometasone, can reduce polyp size and is often used for initial treatment, sometimes in combination with nasal saline irrigation.2 A short course of an oral steroid can be used to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Mometasone-Eluting Sinus Implant (Sinuva) for Nasal Polyps
Article code: 1555e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian